Bevantolol hydrochloride（Cat No.:R056341）is a cardiovascular agent classified as a non-selective β-adrenergic receptor antagonist with additional calcium channel blocking activity. This dual mechanism helps reduce heart rate, myocardial contractility, and vascular resistance, making it effective in lowering blood pressure and controlling angina symptoms. Investigated for use in hypertension and arrhythmias, bevantolol offers potential therapeutic benefits by combining β-blockade with vasodilatory effects. Although not widely marketed, it remains of interest in cardiovascular pharmacology research as a prototype drug for dual-action antihypertensive and antianginal therapy development.